Extract to table
Pull the structured facts out of a document: parties, dates, amounts, obligations.
Extract to table / sec-disclosure-analysis-memo.docx
sec-disclosure-analysis-memo.docx
Parties
Harkness LLP
Global Tax Penterra Pharmaceuticals Corp
General Counsel Penterra Pharmaceuticals Corp
Penterra Pharmaceuticals Corp
Associates LLP
Ridgeview Capital Management LP
Key Stakeholders Penterra Pharmaceuticals Corp
Dates
November 20, 2023
December 31, 2023
October 12, 2023
November 8, 2023
December 22, 2023
May 16, 2022
December 31, 2020
September 20, 2022
March 31, 2024
Amounts
$380.4
$79.88
$15.98
$95.86
$62.4
$1.5
$6.82
$1.47
$235.01
$188.04
Obligations
The IRS has now formally articulated its position and quantified the proposed adjustments, and PPC is required to either accept those adjustments or pursue formal administrative appeal
It is our view that the IRS examination and proposed adjustments must be disclosed in Part I, Item 3 of PPC's Form 10-K for the fiscal year ending December 31, 2023
86 million — constitute a known uncertainty that must be addressed in MD&A
the future event or events are likely to occur) must be accrued if the amount of the loss can be reasonably estimated
the chance of the future event or events occurring is more than remote but less than likely) must be disclosed, including an estimate of the possible loss or range of loss, or a statement that such an estimate cannot be made
However, the NOPA is a new factor that must be weighed in the overall assessment